The COVID Advisor

Dr. Peter McCullough’s X Post (March 25, 2025) Academic Medical Centers have Not Updated Doctors and Patients on the Long-Lasting Spike Protein ( X post ) MedRxiv Preprint (February 18, 2025) Title: Immunological and Antigenic Signatures Associated with Chronic Illnesses after COVID-19 Vaccination ( MedRxiv ) Key Points (Based on Web Result Summaries): This is the primary source of the Yale study, led by Akiko Iwasaki and colleagues. It confirms that some PVS participants had detectable SARS-CoV-2 spike protein in their bloodstream, with persistence up to 709 days post-vaccination. The study highlights immune dysregulation and increased markers of inflammation in PVS patients. As a preprint, this study has not yet been peer-reviewed, meaning its findings are preliminary and subject to further scrutiny. Yale News Article (February 19, 2025) Title: " Immune markers of post-vaccination syndrome indicate future research directions " Key Points: The article discusses a Yale stu...

Abstract: Low-cost systemic treatments, including ivermectin, hydroxychloroquine (HCQ), metformin, antiandrogens, antihistamine H1RAs, curcumin, melatonin, colchicine, probiotics, azvudine, N-acetylcysteine (NAC), fluvoxamine, nigella sativa, famotidine, and quercetin, demonstrate significant efficacy against SARS-CoV-2. This systematic review synthesizes evidence from 423 HCQ studies, 105 ivermectin studies, and numerous trials for other treatments, supported by in silico, in vitro, and animal studies. Early treatment and prophylaxis with HCQ show strong efficacy (p<0.0000000001)*, with the largest RCT reporting 57% lower symptomatic PCR+ COVID-19 (p=0.0002). Ivermectin exhibits efficacy across prophylaxis (96% lower high viral load cases), early, and late treatment (p<0.0000000001), with 36% lower long COVID risk (p<0.0001). Polytherapy enhances outcomes (68% [57-77%] risk reduction) compared to monotherapy (33% [30-36%]), driven by synergistic effects. Despite challenges li...